SciLnq provides senior therapeutic antibody development expertise to biotech companies advancing promising antibody candidates. Our consultants work directly alongside sponsor teams to assess developability, identify candidate liabilities, guide optimization, evaluate manufacturability, strengthen CMC readiness, and support critical development decisions.

​

Unlike a traditional antibody CRO, SciLnq operates as an extension of the sponsor team, combining scientific judgment with hands-on execution while complementing internal capabilities and external partners. This model helps maintain scientific continuity, direct oversight, and more efficient use of development resources as programs advance.